GENAS claims that change in reimbursement status of drugs will lead to increase in additional payments for patients
…drugs. The Ministry, conversely, argues that it is trying to create clear and predictable conditions for both kinds of pharmaceutical companies and for patients. A drug containing the same substance will have an identical reimbursement status in the eyes of the health insurance company.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)